ARS Pharma Files Q3 2024 10-Q/A Amendment

TL;DR

ARS Pharma amended its Q3 2024 10-Q. Check for updates.

AI Summary

ARS Pharmaceuticals, Inc. filed an amendment (10-Q/A) on December 6, 2024, for the quarterly period ending September 30, 2024. The company, formerly Silverback Therapeutics, Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector. This filing is an amendment to their previous quarterly report.

Why It Matters

This amendment provides updated financial and operational information for ARS Pharmaceuticals for the third quarter of 2024, which is crucial for investors to assess the company's performance and outlook.

Risk Assessment

Risk Level: low — This filing is an amendment to a standard quarterly report and does not appear to contain significant new negative information.

Key Players & Entities

• ARS Pharmaceuticals, Inc. (company) — Registrant
• Silverback Therapeutics, Inc. (company) — Former company name
• September 30, 2024 (date) — Quarterly period end date
• December 6, 2024 (date) — Filing date
• Delaware (location) — State of incorporation

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock , par value $0.0001 per share SPRY The Nasdaq Stock Mark

Filing Documents

• d864210d10qa.htm (10-Q/A) — 58KB
• d864210dex311.htm (EX-31.1) — 3KB
• d864210dex312.htm (EX-31.2) — 3KB
• 0001193125-24-272445.txt ( ) — 388KB
• spry-20240930.xsd (EX-101.SCH) — 6KB
• spry-20240930_cal.xml (EX-101.CAL) — 1KB
• spry-20240930_def.xml (EX-101.DEF) — 16KB
• spry-20240930_lab.xml (EX-101.LAB) — 22KB
• spry-20240930_pre.xml (EX-101.PRE) — 17KB
• d864210d10qa_htm.xml (XML) — 28KB

– OTHER INFORMATION

PART II – OTHER INFORMATION Item5. Other Information During the quarter ended September 30, 2024, one of our executive officers terminated a Rule 10b5-1 trading plan and a member of our board of directors adopted a Rule 10b5-1 trading plan, each as set forth in the table below. Type of Trading Arrangement Name and Position Action Adoption/Termination Date Rule 10b5-1 (1) Non-Rule 10b5-1 (2) Total Shares of Common Stock to be Sold Expiration Date Brian Dorsey , Chief Operating Officer Termination (3) August 28, 2024 X 340,000 March 31, 2025 Laura Shawver , Director Adoption August 16, 2024 X 400,002 April 30, 2025 (1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. (2) "Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act. (3) Represents the termination of a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) adopted on March 31, 2023 and amended on December 8, 2023. 1 Item6. Exhibits Exhibit Number Description 31.1 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 101.INS Inline XBRL Instance Document–the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document 101.SCH Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents 104 Cover page formatted as Inline XBRL and contained in Exhibit 101 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ARS PHARMACEUTICALS, INC. Date: December 6, 2024 By: /s/ Richard Lowenthal, M.S., MSEL Richard Lowenthal, M.S., MSEL President and Chief Executive Officer (Principal Executive Officer) Date: December 6, 2024 By: /s/ Kathleen D. Scott Kathleen D. Scott Chief Financial Officer (Principal Financial and Accounting Officer) 3

View Full Filing

View this 10-Q/A filing on SEC EDGAR